To include your compound in the COVID-19 Resource Center, submit it here.

Bayer, Loxo enter $1.6B cancer deal

Loxo Oncology Inc. (NASDAQ:LOXO) and Bayer AG (Xetra:BAYN) partnered on Nov. 14 to develop and commercialize larotrectinib (LOXO-101) and LOXO-195 worldwide. Loxo will receive $400 million up front, and is eligible for $1.2 billion

Read the full 346 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE